At a glance
- Originator Merck & Co
- Class Antidementias; Neuroprotectants
- Mechanism of Action Muscarinic M2 receptor agonists; Muscarinic M3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 26 Jun 2001 No-Development-Reported for Alzheimer's disease in USA (Unknown route)
- 13 Jan 1995 Preclinical development for Alzheimer's disease in USA (Unknown route)